PF-3644022 NEW
Price | $31 | $113 | $213 |
Package | 1mg | 5mg | 10mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-14 |
Product Details
Product Name: PF-3644022 | CAS No.: 1276121-88-0 |
Purity: 98.13% | Supply Ability: 10g |
Release date: 2024/11/14 |
Product Introduction
Bioactivity
名稱 | PF-3644022 |
描述 | PF-3644022 is an effective, selective, and ATP-competitive MAPKAPK2 (MK2) inhibitor (IC50: 5.2 nM and a Ki of 3 nM). PF-3644022 potently inhibits TNFα production and has an anti-inflammatory effect. PF-3644022 also inhibits MK3 and p38 regulated/activated kinase (PRAK) (IC50s: 53 nM and 5.0 nM, respectively). |
體外活性 | PF-3644022 potently inhibits TNFα production with similar activity (IC50 of 160 nM), in the human U937 monocytic cell line or peripheral blood mononuclear cells. PF-3644022 blocks TNFα and IL-6 production in LPS-stimulated human whole blood (IC50: 1.6 and 10.3 μM, respectively). The inhibitory activity of PF-3644022 against other MAPKAP kinase family members is evaluated. Other than MNK2 with an IC50 of 148 nM, other family members are largely not inhibited, showing at least several hundred-fold selectivity versus MK2[1]. |
體內(nèi)活性 | PF-3644022 (3-100 mg/kg; oral gavage; twice daily for 12 days; Lewis rats) treatment exhibits dose-dependent inhibition of chronic paw swelling, measured on day 21 post-treatment (ED50: 20 mg/kg)[1]. |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 41.67 mg/mL (111.28 mM), Sonication and heating to 80℃ are recommended. |
關(guān)鍵字 | TNFα | safety | PRAK | PF-3644022 | PF3644022 | PF 3644022 | p38 MAPK | orally | monocytic | MK3 | Mitogen-activated protein kinase activated protein kinase 2 | MAPKAPK2 (MK2) | MAPKAP kinase 2 | MAPK activated protein kinase 2 | MAP kinase activated protein kinase 2 | lipopolysaccharide | Inhibitor | inhibit | IL-6 | efficacious | Anti-inflammatory |
相關(guān)產(chǎn)品 | Exarafenib | Doramapimod | PMSF | Nafamostat mesylate | Vemurafenib | AEBSF hydrochloride | sodium lauroyl-α-hydroxyethyl sulfonate | Bakuchiol | SB 202190 | (-)-Bornyl acetate | MW-150 | Benzamidine hydrochloride |
相關(guān)庫 | 抗結(jié)直腸癌化合物庫 | 神經(jīng)再生化合物庫 | 經(jīng)典已知活性庫 | 疼痛相關(guān)化合物庫 | 激酶抑制劑庫 | 蛋白酶抑制劑庫 | 抑制劑庫 | NO PAINS 化合物庫 | 抗衰老化合物庫 | 免疫/炎癥分子化合物庫 | 已知活性化合物庫 | 抗癌化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/1G |
VIP4Y
|
Wuhan Nutra Biotechnology Co.,Ltd
|
2022-05-28 | |
$0.00/1gram |
VIP3Y
|
Wuhan Senwayer Century Chemical Co.,Ltd
|
2022-12-08 | |
$0.00/10g |
VIP3Y
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2024-09-20 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY